Ticker: TMO

Thermo Fisher Scientific

Healthcare Healthcare Medical - Diagnostics & Research

Price 693.02

Reco Hold Potential 66 Risk 42 Updated 2026-10-27

Official website

Forecast impact

limited

Target +5.3% target fill 94.9%

Reaction D5 +0.06% · D10 pending fresh confirmed · market trust

Impact Potential 0 · Risk 0 valid until 2026-11-21

Track in portfolio

Price chart

AI recommendation Analyst forecast Calendar event Positive signal Negative signal Neutral / update Hold / informational B My buy S My sell

Description

Company and Business Model

Thermo Fisher Scientific is a leading provider of scientific instruments, reagents, and consumables, primarily serving the healthcare and life sciences sectors. Its core products include analytical instruments, laboratory equipment, and diagnostic tools. Major business segments encompass Life Sciences Solutions, Analytical Instruments, and Specialty Diagnostics, with revenue primarily generated from sales of laboratory equipment and reagents. The company focuses on enhancing research and clinical workflows, contributing to advancements in healthcare and scientific research.

Investment Profile

The investment profile of Thermo Fisher Scientific is more aligned with balanced investors, given its stable revenue growth and modest dividend yield. The company demonstrates consistent performance, making it suitable for those seeking a mix of capital appreciation and income. The stock's moderate volatility and solid fundamentals suggest a lower risk profile, appealing to investors with a medium to long-term horizon.

Category: Healthcare Sector: Healthcare Industry: Medical - Diagnostics & Research Investment style: Growth Horizon: Long-term Company type: Blue Chip Company type: Market Leader

Fundamental metrics (experimental) Updated: 2026-10-28

EPS (TTM) — earnings per share for the last 12 months, $: 18.22
Revenue QoQ — quarter-over-quarter revenue growth: -9.9%
EPS surprise: 1.9%
20d volatility: 1.6%
Dividend yield: 0.4%
last ex-date: 2026-03-13

AI recommendation changes

Date	Before	After	Reason
2026-10-24	Buy	Hold	Weak revenue growth offsets strong historical performance.
2026-10-15	Hold	Buy	Strong momentum, but revenue decline raises concerns.
2026-10-07	Buy	Hold	Weak fundamentals and negative momentum raise concerns.
2026-09-12	Hold	Buy	Mixed performance; fundamentals show some weakness.
2026-09-05	Buy	Hold	Mixed performance; cautious outlook amid revenue decline.
2026-08-27	Hold	Buy	Strong momentum and solid fundamentals support growth potential.
2026-08-19	Buy	Hold	Mixed performance; fundamentals show some weakness.
2026-08-12	Hold	Buy	Strong momentum, but revenue decline raises concerns.
2026-08-04	Buy	Hold	Mixed performance; cautious due to revenue decline.
2026-07-25	Hold	Buy	Strong momentum, but revenue decline raises concerns.
2026-07-16	Sell	Hold	Mixed performance; cautious due to revenue decline.
2026-07-08	Hold	Sell	Weak fundamentals and negative momentum raise concerns.
2026-06-27	Sell	Hold	Weak fundamentals and high risk limit upside potential.
2026-06-17	Hold	Sell	Weak fundamentals and negative momentum raise concerns.
2026-06-09	Buy	Hold	Weak fundamentals and negative momentum raise concerns.
2026-05-30	Sell	Buy	Solid fundamentals but mixed momentum signals.
2026-05-22	Hold	Sell	Weak momentum and high risk; cautious approach advised.
2026-05-08	—	Hold	Weak momentum and high risk; fundamentals show mixed signals.
2026-05-08	Hold	Hold	Компания демонстрирует стабильный рост выручки, но последние месяцы наблюдается снижение цены акций. Рекомендуется удерживать позицию до улучшения рыночной ситуации.
2026-04-23	Buy	Hold	Компания показывает смешанные результаты на коротких промежутках времени, с недавним падением цен. Однако рост выручки и стабильный EPS указывают на долгосрочные перспективы.
2026-04-15	Hold	Buy	Компания показывает положительную динамику в краткосрочной перспективе, однако негативные тренды за последние два месяца могут указывать на возможные риски. Рекомендуется удерживать акции до более ясной картины.
2026-03-30	Buy	Hold	Компания показывает стабильный рост выручки и положительное значение EPS, однако недавние колебания цен и снижение на длительных интервалах вызывают опасения. Рекомендуется удерживать акции до более ясных сигналов о восс
2026-03-23	Hold	Buy	Компания показывает стабильный рост выручки и положительный сюрприз по прибыли, однако недавнее снижение цен акций на 17.60% за 60 дней вызывает опасения.
2026-03-09	Buy	Hold	Компания показывает стабильный рост выручки и положительные результаты по EPS, однако недавнее снижение цен акций и высокая волатильность вызывают опасения. Рекомендуется удерживать акции до более ясных сигналов о восста
2026-03-01	Hold	Buy	Компания показывает стабильный рост выручки и положительный EPS, однако недавнее снижение цен акций на 12% за 20 дней вызывает опасения. Рекомендуется удерживать акции до прояснения ситуации на рынке.
2026-01-29	Buy	Hold	Компания демонстрирует сильный рост за последние 120 дней, однако недавнее снижение цен может указывать на краткосрочные колебания. Рекомендуется удерживать акции до более ясной картины их дальнейшего движения.

Analyst forecasts

Date	Analyst	Action	Target	Price Then
2026-10-22	UBS	Update	— → 800	686.55
2026-10-22	RBC Capital	Target Raised	580 → 730	687.49
2026-10-22	Stifel Nicolaus	Target Raised	650 → 775	694.02
2026-10-22	Robert W. Baird	Target Raised	723 → 756	694.02
2026-10-22	Barclays	Target Raised	750 → 775	694.02
2026-10-15	RBC Capital	Update	— → 740	673.2
2026-10-15	Guggenheim	Update	— → 740	673.2
2026-10-12	Morgan Stanley	Target Raised	650 → 730	659.6
2026-10-07	Barclays	Target Raised	650 → 750	656.58
2026-09-25	Deutsche Bank	Target Raised	635 → 720	665.25
2026-09-08	UBS	Rating Upgraded	— → 730	603.02
2026-09-03	CLSA	Update	— → 748	608.54
2026-08-05	Stifel Nicolaus	Target Raised	600 → 650	564.75
2026-07-27	Piper Sandler	Target Raised	510 → 600	568.26
2026-07-24	Morgan Stanley	Target Raised	620 → 650	568.26
2026-07-24	RBC Capital	Target Raised	490 → 580	561.09
2026-07-23	Jefferies	Target Raised	585 → 630	572.59998
2026-07-06	Evercore ISI	Target Lowered	575 → 570	511.31
2026-06-26	Bernstein	Update	— → 520	505.75
2026-06-11	Piper Sandler	Update	— → 510	482.04
2026-06-03	HSBC	Update	— → 540	482.08
2026-05-14	RBC Capital	Update	— → 490	448.21
2026-04-27	Morgan Stanley	Target Lowered	670 → 620	472.23001
2026-04-24	Stifel Nicolaus	Target Lowered	700 → 600	467.47
2026-04-24	Robert W. Baird	Target Lowered	653 → 639	466.7
2026-01-30	UBS	Target Raised	590 → 615	579.86
2026-01-30	Wells Fargo	Target Lowered	— → 683	580.08502
2026-01-30	Robert W. Baird	Target Raised	645 → 653	583.12
2026-01-30	Barclays	Target Raised	625 → 650	592.16
2026-01-09	Stifel Nicolaus	Target Raised	583 → 700	606.5
2026-01-05	Evercore ISI	Target Raised	610 → 650	605.83

News Page 1 of 1

Analysts Ritholtz Wealth Management highlight Waters Corporation (WAT) and Thermo Fisher Scientific (TMO) as top healthcare stocks amid sector rotation

10/19/2026, 08:37 AM investing review Analysts: analysts, Ritholtz healthcare Thermo Fisher Scientific Waters Corporation

Healthcare stocks are gaining traction as investors rotate out of AI-focused sectors, with Waters Corporation and Thermo Fisher Scientific highlighted as key beneficiaries. This shift is significant as it reflects changing market dynamics and investor sentiment towards growth areas within healthcare.

Analysts JPMorgan Recommend American Express (AXP), Liberty Energy (LBRT), and Thermo Fisher Scientific (TMO) as Top Stock Picks for October

10/04/2026, 06:31 AM investing recommendation Analysts: analysts, JPMorgan finance energy Thermo Fisher Scientific American Express Liberty Energy

JPMorgan's updated list of favored stocks for October highlights investment opportunities amid a mixed market performance, with specific recommendations for growth and value plays that could appeal to investors navigating current economic uncertainties.

Goldman Sachs Reports 29% Year-to-Date Return for Portfolio of Favorite Stocks, Adding New Members

08/24/2026, 10:38 AM investing review finance SpaceX Capital One Boeing Thermo Fisher Scientific Mastercard Visa

Goldman Sachs identified six stocks favored by both hedge funds and mutual funds, highlighting a significant shift towards financial stocks, which could indicate broader market trends and investment strategies.

S&P 500 Experiences Weekly Loss Despite Surge in Overbought Stocks Including Moderna and Merck

08/22/2026, 05:31 AM investing review Estee Lauder Merck Agilent Technologies Thermo Fisher Scientific Moderna

The S&P 500 experienced a decline after three weeks of gains, primarily due to rising Treasury yields, while several individual stocks, particularly in the healthcare and cosmetics sectors, reached overbought levels following strong earnings and positive trial results.